<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501500</url>
  </required_header>
  <id_info>
    <org_study_id>NSC 99-2314-B-182A-020</org_study_id>
    <nct_id>NCT01501500</nct_id>
  </id_info>
  <brief_title>Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact Insole</brief_title>
  <official_title>Therapeutic Effect of Botulinum Toxin Type A in Addition to Total Contact Insole in Treating Painful Hallux valgus-a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a new therapeutic approach by injecting Botulinum Toxin Type A
      (BTA) to the oblique and transverse heads of adductor muscle of the great toe. BTA works by
      binding presynaptically to high-affinity recognition sites on the cholinergic nerve terminals
      and decrease the release of acetylcholine, causing a neuromuscular blocking effect. The
      investigators hypothesize that BTA injection may help to decrease the hallux valgus angle by
      decrease adductor hallucis muscle activation. Thereby enhance the therapeutic result of
      hallux valgus treated with total contact insole. The outcome measurement may shed light in
      treating patient with painful hallux valgus and document evidence for plantar pressure
      changes in acute, sub-acute and chronic stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled prospective study to assess the
      influence and efficacy of intramuscular (IM) Botulinum Toxin Type A (BTA) injection in
      patients with painful hallux valgus with the use of total contact insole.

      Fifty feet with painful hallux valgus will be collected. Informed consent is obtained
      according to the hospital's medical ethics and the human clinical trial committee. The feet
      will be randomized into 2 groups: Group A (n=25, treatment group) and Group B (n=25, control
      group). Clinical diagnosis of hallux valgus is made based on observation of great toe lateral
      deviation. Inclusion criteria were hallux valgus with angle of at least 20°, single or
      bilateral hallux valgus. To obtain the hallux valgus angle, foot roentgenography in AP and
      sesamoid views under the weight bearing condition will be obtained. The angle formed by lines
      drawn to bisect the first metatarsal bone and the proximal phalanx of the great toe will be
      measured. The exclusion criteria include history of foot operations, rheumatoid and gouty
      arthritis, and any contraindication to BTA administration. Subjective data such as the Foot
      Function Index will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hallux valgus angle</measure>
    <time_frame>up to 18 months</time_frame>
    <description>radiological assessment before and after the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>foot function index for quality of life</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Foot Function Index before and after the intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hallux Valgus</condition>
  <arm_group>
    <arm_group_label>botulinum toxin type A. HV angle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramuscular injection of BTA into target muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline, HV angle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intramuscular injection of normal saline into target muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX</intervention_name>
    <description>once injection of BTA 3oU into hallux oblique and transverse heads each</description>
    <arm_group_label>botulinum toxin type A. HV angle</arm_group_label>
    <other_name>BOTOX (Allergan, Irvine, CA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline (0.9% NaCl)</intervention_name>
    <description>Normal saline 0.3ml to oblique and transverse heads each</description>
    <arm_group_label>Normal saline, HV angle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hallux valgus with angle of at least 20°,

          -  single or bilateral hallux valgus.

        Exclusion Criteria:

          -  history of foot operations,

          -  rheumatoid arthritis and gouty arthritis.

          -  Any contraindication on BTA administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katie P Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung MH</name>
      <address>
        <city>Gueishan</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>botulinum toxin type A</keyword>
  <keyword>hallux valgus angle</keyword>
  <keyword>foot function index</keyword>
  <keyword>VAS pain scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallux Valgus</mesh_term>
    <mesh_term>Bunion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

